| 0.9228 0.01 (1.13%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.43 |
1-year : | 1.69 |
| Resists | First : | 1.23 |
Second : | 1.45 |
| Pivot price | 1.03 |
|||
| Supports | First : | 0.88 | Second : | 0.73 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 1.07 |
| MA(100) : | 1.51 |
MA(250) : | 2.7 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.2 |
D(3) : | 8.2 |
| RSI | RSI(14): 35.6 |
|||
| 52-week | High : | 5.53 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLUE ] has closed above bottom band by 24.5%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.95 | 0.95 - 0.96 |
| Low: | 0.88 - 0.89 | 0.89 - 0.89 |
| Close: | 0.91 - 0.92 | 0.92 - 0.93 |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Apr 2024
Robbins LLP Reminds Investors of Bluebird Bio, Inc. to Contact the Law Firm for Information About the Class Action ... - GlobeNewswire
Fri, 26 Apr 2024
bluebird bio Announces Receipt of Expected Notice from Nasdaq - Business Wire
Fri, 26 Apr 2024
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird ... - GlobeNewswire
Fri, 26 Apr 2024
BLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and ... - PR Newswire
Wed, 24 Apr 2024
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before ... - GlobeNewswire
Sun, 21 Apr 2024
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class ... - AccessWire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 193 (M) |
| Held by Insiders | 1.0882e+008 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 34,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3177e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -683.8 % |
| Return on Assets (ttm) | -15.1 % |
| Return on Equity (ttm) | -47.9 % |
| Qtrly Rev. Growth | 17 % |
| Gross Profit (p.s.) | 441.87 |
| Sales Per Share | 2.71625e+007 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -277 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.35 |
| Dividend | 0 |
| Forward Dividend | 2.975e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|